Prescribing information

__________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________

Commissioned Luxturna Treatment Centres

Where to refer a patient who has confirmed biallelic RPE65 mutations. 

Four centres across the UK have been commissioned by NHS England to administer Luxturna® (voretigene neparvovec) to eligible patients. These centres can be consulted to discuss your RPE65-mutation-associated IRD patients and their potential eligibility for Luxturna.

Please contact us for more information.

 

Contact us

 

Map showing the four centres across the UK that have been commissioned by NHS England to administer LUXTURNA to eligible patients.

IRD, inherited retinal dystrophy; RPE, retinal pigment epithelium.

Indication: Luxturna is indicated for the treatment of adult and paediatric patients with vision loss due to inherited retinal dystrophy caused by confirmed biallelic RPE65 mutations and who have sufficient viable retinal cells.1

Reference     

  1. Luxturna SmPC, 2020.
LUX20-C005c October 2020.
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at http://www.report.novartis.com/
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]